{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:49:20Z","timestamp":1786992560893,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jiac.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T13:32:55Z","timestamp":1689859975000},"page":"1038-1045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6080-1801","authenticated-orcid":false,"given":"Kei","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-0667","authenticated-orcid":false,"given":"Kyoko","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3239-5249","authenticated-orcid":false,"given":"Satoko","family":"Ohfuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-6942","authenticated-orcid":false,"given":"Wakaba","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2023.07.008_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.jiac.2023.07.008_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.07.008_bib3","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non\u2013small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"38","author":"Hanna","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jiac.2023.07.008_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.07.008_bib5","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.07.008_bib6","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.07.008_bib7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.07.008_bib8","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.07.008_bib9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.07.008_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jinf.2014.10.008","article-title":"The association between infections and chemotherapy interruptions among cancer patients: prospective cohort study","volume":"70","author":"Taha","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.jiac.2023.07.008_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.21203","article-title":"Epidemiology and outcomes of serious influenza-related infections in the cancer population","volume":"104","author":"Cooksley","year":"2005","journal-title":"Cancer"},{"issue":"58","key":"10.1016\/j.jiac.2023.07.008_bib12","first-page":"309","article-title":"IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"2014","author":"Rubin","year":"2013","journal-title":"Clin Infect Dis : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.jiac.2023.07.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021\u201322 influenza season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.jiac.2023.07.008_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/21645515.2016.1246094","article-title":"Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy","volume":"13","author":"Nakashima","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jiac.2023.07.008_bib15","first-page":"CD008983","article-title":"Influenza vaccines in immunosuppressed adults with cancer","volume":"2","author":"Bitterman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiac.2023.07.008_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13604","article-title":"Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: a systematic review","volume":"51","author":"Spagnolo","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jiac.2023.07.008_bib17","article-title":"Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor","author":"Keam","year":"2019","journal-title":"Clin Infect Dis : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.jiac.2023.07.008_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciz202","article-title":"Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors","volume":"70","author":"Chong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.07.008_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1084\/jem.75.1.49","article-title":"The quantitative determination of influenza virus and antibodies by means of red cell agglutination","volume":"75","author":"Hirst","year":"1942","journal-title":"J Exp Med"},{"key":"10.1016\/j.jiac.2023.07.008_bib20","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jiac.2023.07.008_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-018-0353-7","article-title":"Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events","volume":"6","author":"Laubli","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jiac.2023.07.008_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/1348-0421.12316","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan","volume":"59","author":"Tsurudome","year":"2015","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.jiac.2023.07.008_bib23","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.vaccine.2016.06.064","article-title":"Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: a systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Moa","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2023.07.008_bib24","series-title":"Clinical data needed to support the licensure of seasonal inactivated influenza vaccines","author":"Centor for Biologics Evaluation and Research Guidance for Industry","year":"2007"},{"key":"10.1016\/j.jiac.2023.07.008_bib25","first-page":"197","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults in Japan","volume":"7","author":"Naoaki Watanabe","year":"2018","journal-title":"Annals of the Japanese Respiratory Society"},{"key":"10.1016\/j.jiac.2023.07.008_bib26","series-title":"Notefor guidance on harmmonisation of requirements for in-fluenza vaccines","year":"1997"},{"key":"10.1016\/j.jiac.2023.07.008_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2020.03.290","article-title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","volume":"31","author":"Bayle","year":"2020","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.jiac.2023.07.008_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002619","article-title":"INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)","volume":"9","author":"Bersanelli","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jiac.2023.07.008_bib29","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s11606-020-06187-1","article-title":"Better patient experience is associated with better vaccine uptake in older adults: multicentered cross-sectional study","volume":"35","author":"Kaneko","year":"2020","journal-title":"J Gen Intern Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23001708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23001708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:06:01Z","timestamp":1761159961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X23001708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1341321X23001708"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.07.008","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}